A054670 Share Price Performance
₩7,080.00
-1360.00 (-16.11%)
Price ₩7,080.00
Share Price₩7,080.00
A054670 Community Narratives
There are no narratives available yet.
Recent A054670 News & Updates
No updates
Daehan Nupharm Co.,Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 914.02
- Gross Margin
- 47.28%
- Net Profit Margin
- 6.23%
- Debt/Equity Ratio
- 54.4%
Daehan Nupharm Co.,Ltd. Competitors
About A054670
- Founded
- 1984
- Employees
- n/a
- CEO
- WebsiteView website
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products. The company also provides animal health and nutrition products; health supplements; and aesthetic/medical devices. The company was formerly known as Daehan New Pharm Co., Ltd and changed its name to Daehan Nupharm Co.,Ltd. in March 2025. Daehan Nupharm Co.,Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.
South Korean Market Performance
- 7 Days: -2.5%
- 3 Months: 19.8%
- 1 Year: 13.3%
- Year to Date: 27.4%
Over the last 7 days, the market has dropped 2.5%, driven by a pullback of 8.3% in the Financials sector. In the last year, the market is actually up 13%. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading